Targeting the STAT pathway in head and neck cancer: Recent advances and future prospects

Current Cancer Drug Targets

Volumn 4, Issue 8, 2004, Pages 637-651

  Nikitakis, N G ^a,b,c   Siavash, H ^a   Sauk, J J ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Head and neck; Signal transducer and activator of transcription (STAT); Squamous cell carcinoma; Targeting therapies for cancer

Indexed keywords

STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR;

CELL PROLIFERATION; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; MEDICAL RESEARCH; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; DNA, ANTISENSE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; MILK PROTEINS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 10944245682     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332736     Document Type: Review

References (180)

1. Vokes, E. E.; Weichselbaum, R. R.; Lippman, S. M., Hong, W. K. Head and neck cancer. N. Engl. J. Med. 1993, 328, 184-194.
2. Boyle, P.; Macfarlane, G. J.; Zheng, T.; Maisonneuve, P.; Evstifeeva, T.; Scully, C. Recent advances in epidemiology of head and neck cancer. Curr. Opin. Oncol. 1992, 4, 471-477.
3. Babu, K. G. Oral cancers in India. Semin. Oncol. 2001, 28, 169-173.
4. Song, J. I.; Grandis, J. R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489-2495.
5. Dhooge, I. J.; De Vos, M; Van Cauwenberge, P. B. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998, 108, 250-256.
6. Todd, R.; Donoff, R. B.; Wong, D. T. The molecular biology of oral carcinogenesis: toward a tumor progression model. J. Oral. Maxillofac. Surg. 1997, 55, 613-623.
7. Williams, H. K. Molecular pathogenesis of oral squamous carcinoma. Mol. Pathol. 2000, 53, 165-172.
8. Loro, L. L.; Vintermyr, O. K.; Johannessen, A. C. Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J. Oral Pathol. Med. 2003, 32, 125-138.
9. Maestro, R.; Dolcetti, R.; Gasparotto, D.; Doglioni, C.; Pelucchi, S.; Barzan, L.; Grandi, E.; Boiocchi, M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992, 7, 1159-1166.
10. Ahomadegbe, J. C.; Barrois, M.; Fogel, S.; Le Bihan, M. L.; Douc-Rasy, S., Duvillard, P; Armand, J. P.; Riou, G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995, 10, 1217-1227.
11. Jares, P.; Fernandez, P. L.; Campo, E.; Nadal, A.; Bosch, F.; Aiza, G.; Nayach, I.; Traserra, J.; Cardesa, A. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 1994, 54, 4813-4817.
12. Callender, T.; el Naggar, A. K.; Lee, M. S.; Frankenthaler, R.; Luna, M. A.; Batsakis, J. G. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994, 74, 152-158.
13. Ozanne, B.; Richards, C. S.; Hendler, F.; Burns, D.; Gusterson, B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J. Pathol 1986, 149, 9-14.
14. Maxwell, S. A.; Sacks, P. G.; Gutterman, J. U.; Gallick, G. E. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res. 1989, 49, 1130-1137.
15. Darnell J. E. Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 740-749.
16. Darnell J. E. Jr. STATs and gene regulation. Science 1997, 277, 1630-1635.
17. Bromberg, J.; Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468-2473.
18. Zhong, Z.; Wen, Z.; Darnell, J. E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264, 95-98.
19. Darnell, J. E. Jr.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421.
20. Schindler, C.; Darnell, J. E. Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 1995, 64, 621-651.
21. Takeda, K.; Akira, S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000, 11, 199-207.
22. Levy, D. E.; Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3, 651-662.
23. Levy, D. E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell Mol. Life Sci. 1999, 55, 1559-1567.
24. Rane, S. G.; Reddy, E. P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19, 5662-5579.
25. Chaturvedi, P; Sharma, S; Reddy, E. P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell Biol. 1997, 17, 3295-3304.
26. Olayioye, M. A.; Beuvink, I.; Horsch, K.; Daly, J. M.; Hynes, N. E. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J. Biol. Chem. 1999, 274, 17209-17218.
27. Wang, Y. Z.; Wharton, W.; Garcia, R.; Kraker, A.; Jove, R.; Pledger, W. J. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 2000, 19, 2075-2085.
28. Garcia, R.; Bowman, T. L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C. A.; Cox, C. E.; Falcone, R.; Fairclough, R.; Parsons, S.; Laudano, A.; Gazit, A.; Levitzki, A.; Kraker, A.; Jove, R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20, 2499-2513.
29. Schreiner, S. J.; Schiavone, A. P.; Smithgall, T. E. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem. 2002, 277, 45680-45687.
30. Seidel, H. M.; Milocco, L. H.; Lamb, P.; Darnell, J. E. Jr.; Stein, R. B.; Rosen, J. Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 1995, 92, 3041-3045.
31. Ehret, G. B.; Reichenbach, P.; Schindler, U.; Horvath, C. M.; Fritz, S.; Nabholz, M.; Bucher, P. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 2001, 276, 6675-6688.
32. Vinkemeier, U.; Cohen, S. L.; Moarefi, I.; Chait, B. T.; Kuriyan, J.; Darnell, J. E. Jr. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO. J. 1996, 15, 5616-5626.
33. Shuai, K.; Liao, J.; Song, M. M. Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Mol. Cell Biol. 1996, 16, 4932-4941.
34. Strehlow, I.; Schindler, C. Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation. J. Biol. Chem. 1998, 273, 28049-28056.
35. Yang, E.; Henriksen, M. A.; Schaefer, O.; Zakharova, N.; Darnell, J. E. Jr. Dissociation time from DNA determines transcriptional function in a STAT1 linker mutant. J. Biol. Chem. 2002, 277, 13455-13462.
36. Gupta, S.; Van, H.; Wong, L. H.; Ralph, S.; Krolewski, J.; Schindler, C. The SH2 domains of Stat1 and Stat2 mediate multiple interactions in the transduction of IFN-alpha signals. EMBO J. 1996, 15, 1075-1084.
37. Wen, Z.; Zhong, Z.; Darnell, J. E. Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82, 241-250.
38. Bromberg, J. F.; Horvath, C. M.; Besser, D.; Lathem, W. W.; Darnell, J. E. Jr. Stat3 activation is required for cellular transformalion by v-src. Mol. Cell Biol. 1998, 18, 2553-2558.
39. Turkson, J.; Bowman, T.; Adnane, J.; Zhang, Y.; Djeu, J. Y.; Sekharam, M.; Frank, D. A.; Holzman, L. B.; Wu, J.; Sebti, S.; Jove, R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell Biol. 1999, 19, 7519-7528.
40. Moriggl, R.; Berchtold, S.; Friedrich, K.; Standke, G. J.; Kammer, W.; Heim, M.; Wissler, M.; Stocklin, E.; Gouilleux, F.; Groner, B. Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Mol. Cell Biol. 1997, 17, 3663-3678.
41. Kim, H.; Baumann, H. The carboxyl-terminal region of STAT3 controls gene induction by the mouse haptoglobin promoter. J. Biol. Chem. 1997, 272, 14571-14579.
42. Leonard, W. J.; O'Shea, J. J. Jaks and STATs: biological implications. Annu. Rev. Immunol. 1998, 16, 293-322.
43. Hoey, T.; Schindler, U. STAT structure and function in signaling. Curr. Opin. Genet. Dev. 1998, 8, 582-587.
44. Krebs, D. L.; Hilton, D. J. SOCS proteins: negative regulators of cytokine signaling. Stem. Cell 2001, 19, 378-387.
45. Kile, B. T.; Nicola, N. A.; Alexander, W. S. Negative regulators of cytokine signaling. Int. J. Hematol. 2001, 73, 292-298.
46. Starr, R.; Hilton, D. J. SOCS: suppressors of cytokine signalling. Int. J. Biochem. Cell Biol. 1998, 30, 1081-1085.
47. Starr, R.; Hilton, D. J. Negative regulation of the JAK/STAT pathway. Bioessays 1999, 21, 47-52
48. Kile, B. T.; Alexander, W. S. The suppressors of cytokine signalling (SOCS). Cell Mol. Life Sci. 2001, 58, 1627-1635.
49. David, M.; Chen, H. E.; Goelz, S.; Larner, A. C.; Neel, B. G. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTPI. Mol. Cell Biol. 1995, 15, 7050-7058.
50. You, M.; Yu, D. H.; Feng, G. S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell Biol. 1999, 19, 2416-2424.
51. Aoki, N.; Matsuda, T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J. Biol. Chem. 2000, 275, 39718-39726.
52. Qu, C. K. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim. Biophys. Acta 2002, 1592, 297-301.
53. Xia, L.; Wang, L.; Chung, A. S.; Ivanov, S. S.; Ling, M. Y.; Dragoi, A. M.; Platt, A.; Gilmer, T. M.; Fu, X. Y.; Chin, Y. E. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J. Biol. Chem. 2002, 277, 30716-30723.
54. Chung, C. D.; Liao, J.; Liu, B.; Rao, X.; Jay, P.; Berta, P.; Shuai, K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997, 278, 1803-1805.
55. Shuai, K. Modulation of STAT signaling by STAT-interacting proteins. Oncogens 2000, 19, 2638-2644.
56. Caldenhoven, E.; van Dijk, T. B.; Solari, R.; Armstrong, J.; Raaijmakers, J. A.; Lammers, J. W.; Koenderman, L.; de Groot, R. P. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 1996, 271, 13221-13227.
57. ten Hoeve, J.; de Jesus Ibarra-Sanchez, M.; Fu, Y.; Zhu, W.; Tremblay, M.; David, M.; Shuai, K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell Biol. 2002, 22, 5662-5668.
58. Decker, T.; Kovarik, P. Serine phosphorylation of STATs. Oncogens 2000, 19, 2628-2637.
59. Wen, Z.; Darnell, J. E. Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997, 25, 2062-2067.
60. Chung, J.; Uchida, E.; Crammer, T. C.; Blenis, J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell Biol. 1997, 17, 6508-6516.
61. Jain, N.; Zhang, T.; Fong, S. L.; Lim, C. P.; Cao, X. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene 1998, 17, 3157-3167.
62. Sengupta, T. K.; Talbot, E. S.; Scherle, P. A.; Ivashkiv, L. B. Rapid inhibition of interleukin-6 signaling and Stau activation mediated by mitogen-activated protein kinases. Proc. Natl. Acad. Sci. USA 1998, 95, 11107-11112.
63. Pircher, T. J.; Petersen, H.; Gustafsson, J. A.; Haldosen, L. A. Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol. Endocrinol. 1999, 13, 555-565.
64. Bode, J. G.; Ludwig, S.; Freitas, C. A.; Schaper, F.; Ruhl, M.; Melmed, S.; Heinrich, P. C.; Haussinger, D. The MKK6/p38 mitogen-activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-induced transcription. Biol. Chem. 2001, 382, 1447-1453.
65. Bode, J. G.; Nimmesgern, A.; Schmitz, J.; Schaper, F.; Schmitt, M.; Frisch, W.; Haussinger, D.; Heinrich, P. C.; Graeve. L. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett. 1999, 463, 365-370.
66. Ahmed, S. T.; Ivashkiv, L. B. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J. Immunol. 2000, 165, 5227-5237.
67. Ahmed, S. T.; Mayer, A.; Ji, J. D.; Ivashkiv, L. B. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J. Leukoc. Biol. 2002, 72, 154-162.
68. Lim, C. P.; Cao, X. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem. 1999, 274, 31055-31061.
69. Steinman, R. A.; Wentzel, A.; Lu, Y.; Stehle, C.; Grandis, J. R. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene 2003, 22, 3608-3615.
70. Zhang, J.; Yang, J.; Roy, S. K.; Tininini, S.; Hu, J.; Bromberg, J. F.; Poli, V.; Stark, G. R.; Kalvakolanu, D. V. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc. Natl. Acad. Sci. USA 2003, 100, 9342-9347.
71. Lufei, C.; Ma, J.; Huang, G.; Zhang, T.; Novotny-Diermayr, V.; Ong, C. T.; Cao, X. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J. 2003, 22, 1325-1335.
72. Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene 2000, 19, 2474-2488.
73. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109, 1139-1142.
74. Brom berg, J. F. Activation of STAT proteins and growth control. Bioessays 2001, 23, 161-169.
75. Migone, T. S.; Lin, J. X.; Cereseto, A.; Mulloy, J. C.; O'Shea, J. J.; Franchini, G.; Leonard, W. J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1 Science 1995, 269, 79-81.
76. Yu, C. L.; Meyer, D. J.; Campbell, G. S.; Larner, A. C.; Carter-Su, C.; Schwartz, J.; Jove, R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269, 81-83.
77. Lund, T. C.; Garcia, R.; Medveczky, M. M.; Jove, R.; Medveczky, P. G. Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck. J. Virol. 1997, 71, 6677-6682.
78. Garcia, R.; Yu, C. L.; Hudnall, A.; Catlett, R.; Nelson, K. L.; Smithgall, T.; Fujita, D. J.; Ethier, S. P.; Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoprotcins and in breast carcinoma cells. Cell Growth Differ. 1997, 8, 1267-1276.
79. Zong, C. S.; Zeng, L.; Jiang, Y.; Sadowski, H. B.; Wang, L. H. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem. 1998, 273, 28065-28072.
80. Wen, X.; Lin, H. H.; Shih, H. M.; Kung, H. J.; Ann, D. K. Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J. Biol. Chem. 1999, 274, 38204-38210.
81. Schwaller, J.; Frantsve, J.; Aster, J.; Williams, I. R.; Tomasson, M. H.; Ross, T. S.; Peeters, P.; Van Rompaey, L.; Van Etten, R. A.; Illaria, R. Jr.; Marynen, P.; Gilliland, D. G. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998, 17, 5321-5333.
82. Cao, X.; Tay, A.; Guy, G. R.; Tan, Y. H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell Biol. 1996, 16, 1595-1603.
83. Bromberg, J. F.; Wrzeszczynska, M. H.; Devgan, G.; Zhao, Y.; Pestell, R. G.; Albanese, C.; Darnell, J. E. Jr. Stat3 as an oncogene. Cell 1999, 98, 295-303.
84. Yu, H.; Jove, R. The STATs of cancernew molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.
85. Grandis, J. R.; Drenning, S. D.; Chakraborty, A.; Zhou, M. Y.; Zeng, Q.; Pitt, A. S.; Tweardy, D. J. Requirement of Stat3 but not Stat1 activation for epidermal growlh factor receptor-mediated cell growth in vitro. J. Clin. Invest. 1998, 102, 1385-1392.
86. Chin, Y. E.; Kitagawa, M.; Su, W. C.; You, Z. H.; Iwamoto, Y.; Fu, X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272, 719-722.
87. Chin, Y. E.; Kitagawa, M.; Kuida, K.; Flavell, R. A.; Fu, X. Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell Biol. 1997, 17, 5328-5337.
88. Sahni, M.; Ambrosetti, D. C.; Mansukhani, A.; Gertner, R.; Levy, D.; Basilico, C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999, 13, 1361-1366.
89. Kaplan, D. H.; Shankaran, V.; Dighe, A. S.; Stocken, E.; Aguet, M.; Old, L. J.; Schreiber, R. D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 1998, 95, 7556-7561.
90. Catlett-Falcone, R.; Landowski, T. H.; Oshiro, M. M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernandez-Luna, J. L.; Nunez, G.; Dalton, W. S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10, 105-115.
91. Lou, W.; Ni, Z.; Dyer, K.; Tweardy, D. J.; Gao, A. C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000, 42, 239-242.
92. Fernandes, A.; Hamburger, A. W.; Gerwin, B. I. ErbB-2 kinase is required for constitulive stat 3 activation in malignant human lung epithelial cells. Int. J. Cancer 1999, 83, 564-570.
93. Turkson, J.; Bowman, T.; Garcia, R.; Caldenhoven, E.; De Groot, R. P.; Jove, R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 1998, 18, 2545-2552.
94. Zhang, Y.; Turkson, J.; Carter-Su, C.; Smithgall, T.; Levitzki, A.; Kraker, A.; Krolewski, J. J.; Medveczky, P.; Jove, R. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 2000, 275, 24935-24944.
95. Shuai, K.; Halpern, J.; ten Hoeve, J.; Rao, X.; Sawyers, C. L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13, 247-254.
96. Danial, N. N.; Losman, J. A.; Lu, T.; Yip, N.; Krishnan, K.; Krolewski, J.; Goff, S. P.; Wang, J. Y.; Rothman, P. B. Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol. Cell Biol. 1998, 18, 6795-6804.
97. Danial, N. N.; Rothman, P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000, 19, 2523-2531.
98. Yoshikawa, H.; Matsubara, K.; Qian, G. S.; Jackson, P.; Groopman, J. D.; Manning, J. E.; Harris, C. C.; Herman, J. G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28, 29-35.
99. Calm, O.; Yoshikawa, H.; Esteller, M.; Osieka, R.; Herman, J. G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101, 2784-2788.
100. Nagai, H.; Naka, T.; Terada, Y.; Komazaki, T.; Yabe, A.; Jin, E.; Kawanami, O.; Kishimoto, T.; Konishi, N.; Nakamura, M.; Kobayashi, Y.; Emi, M. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J. Hum. Genet. 2003, 48, 65-69.
101. Chen, C. Y.; Tsay, W.; Tang, J. L.; Shen, H. L.; Lin, S. W.; Huang, S. Y.; Yao, M.; Chen, Y. C.; Shen, M. C.; Wang, C. H.; Tien, H. F. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 2003, 37, 300-305.
102. Fukushima, N.; Sato, N.; Sahin, F.; Su, G. H.; Hruban, R. H.; Goggins, M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br. J. Cancer 2003, 89, 338-343.
103. Zhang, Q.; Raghunath, P. N.; Xue, L.; Majewski, M.; Carpentieri, D. F.; Odum, N.; Morris, S.; Skorski, T.; Wasik, M. A. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. 2002, 168, 466-474.
104. Grandis, J. R.; Drenning, S. D.; Zeng, Q.; Watkins, S. C.; Melhem, M. F.; Endo, S.; Johnson, D. E.; Huang, L.; He, Y.; Kim, J. D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 4227-4232.
105. Lord, J. D.; McIntosh, B. C.; Greenberg, P. D.; Nelson, B. H. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 2000, 164, 2533-2541.
106. Socolovsky, M.; Fallen, A. E.; Wang, S.; Brugnara, C.; Lodish, H. F. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98, 181-191.
107. Dumon, S.; Santos, S. C.; Debierre-Grockiego, F.; Gouilleux-Gruart, V.; Cocault, L.; Boucheron, C.; Mollat, P.; Gisselbrecht, S.; Gouilleux, F. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 1999, 18, 4191-4199.
108. Silva, M.; Benito, A.; Sanz, C.; Prosper, F.; Ekhterae, D.; Nunez, G.; Fernandez-Luna, J. L. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 1999, 274, 22165-22169.
109. Gesbert, F.; Griffin, J. D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000, 96, 2269-2276.
110. Horita, M.; Andreu, E. J.; Benito, A.; Arbona, C.; Sanz, C.; Be'net, I.; Prosper, F.; Fernandez-Luna, J. L. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 2000, 191, 977-984.
111. Epling-Burnette, P. K.; Liu, J. H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J. M.; Yang-Yen, H. F.; Karras, J.; Jove, R.; Loughran, T. P. Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 2001, 107, 351-362.
112. Huang, M.; Dorsey, J. F.; Epling-Burnette, P. K.; Nimmanapalli, R.; Landowski, T. H.; Mora, L. B.; Niu, G.; Sinibaldi, D.; Bai, F.; Kraker, A.; Yu, H.; Moscinski, L.; Wei, S.; Djeu, J.; Dalton, W. S.; Bhalla, K.; Loughran, T. P.; Wu, J.; Jove, R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002, 21, 8804-8816.
113. Kanda, N.; Seno, H.; Konda, Y.; Marusawa, H.; Kanai, M.; Nakajima, T.; Kawashima, T.; Nanakin, A.; Sawabu, T.; Uenoyama, Y.; Sekikawa, A.; Kawada, M.; Suzuki, K.; Kayahara, T.; Fukui, H.; Sawada, M.; Chiba, T. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23, 4921-4929.
114. Aoki, Y.; Feldman, G. M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101, 1535-1542.
115. Bowman, T.; Broome, M. A.; Sinibaldi, D.; Wharton, W.; Pledger, W. J.; Sedivy, J. M.; Irby, R.; Yeatman, T.; Courtneidge, S. A.; Jove, R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 7319-7324.
116. Sinibaldi, D.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger, W. J.; Jove, R. Induction of p21 WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000, 19, 5419-5427.
117. Masuda, M.; Suzui, M.; Yasumatu, R.; Nakashima, T.; Kuratomi, Y.; Azuma, K.; Tomita, K.; Komiyama, S.; Weinstein, I. B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002, 62, 3351-3355.
118. Martino, A.; Holmes, J. H.; Lord, J. D.; Moon, J. J.; Nelson, B. H. Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2. J. Immunol. 2001, 166, 1723-1729.
119. Niu, G.; Wright, K. L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L. M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.
120. Wei, L. H.; Kuo, M. L.; Chen, C. A.; Chou, C. H.; Lai, K. B.; Lee, C. N.; Hsieh, C. Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22, 1517-1527.
121. Yahata, Y.; Shirakata, Y.; Tokumaru, S.; Yamasaki, K.; Sayama, K..; Hanakawa, Y.; Detmar, M.; Hashimoto, K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem. 2003, 278, 40026-40031.
122. Deo, D. D.; Axelrad, T. W.; Robert, E. G.; Marcheselli, V.; Bazan, N. G.; Hunt, J. D. Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J. Biol. Chem. 2002, 277, 21237-21245.
123. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10, 48-54.
124. Cheng, F.; Wang, H. W.; Cuenca, A.; Huang, M.; Ghansah, T.; Brayer, J.; Kerr, W. G.; Takeda, K.; Akira, S.; Schoenberger, S. P.; Yu, H.; Jove, R.; Sotomayor, E. M. A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19, 425-436.
125. Kjjima, T.; Niwa, H.; Steinman, R. A.; Drenning, S. D.; Gooding, W. E.; Wentzel, A. L.; Xi, S.; Grandis, J. R. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002, 13, 355-362.
126. Grandis, J. R.; Zeng, Q.; Drenning, S. D. Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 2000, 110, 868-874.
127. Leong, P. L.; Xi, S.; Drenning, S. D.; Dyer, K. F.; Wentzel, A. L.; Lerner, E. C.; Smithgall, T. E.; Grandis, J. R. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002, 21, 2846-2853.
128. Xi, S.; Zhang, Q.; Gooding, W. E.; Smithgall, T. E.; Grandis, J. R. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 2003, 63, 6763-6771.
129. Nagpal, J. K.; Mishra, R.; Das, B. R. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002, 94, 2393-2400.
130. Arany, I.; Chen, S. H.; Megyesi, J. K.; Adler-Storthz, K.; Chen, Z.; Rajaraman, S.; Ember, I. A.; Tyring, S. K.; Brysk, M. M. Differentiation- dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett. 2003, 199, 83-89.
131. Masuda, M.; Suzui, M.; Lim, J. T.; Deguchi, A.; Soh, J. W.; Weinstein, I. B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol 2002, 2, 350-359.
132. Lango, M.; Wentzel, A. L.; Song, J. I.; Xi, S.; Johnson, D. E.; Lamph, W. W.; Miller, L.; Grandis, J. R. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clin. Cancer Res. 2003, 9, 4205-4213.
133. Xi, S.; Zhang, Q.; Dyer, K. F.; Lerner, E. C.; Smithgall, T. E.; Gooding, W. E.; Kamens, J.; Grandis, J. R. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. 2003, 278, 31574-31583.
134. Sriuranpong, V.; Park, J. I.; Amornphimoltham, P.; Patel, V.; Nelkin, B. D.; Gutkind, J. S. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003, 63, 2948-2956.
135. Siavash, H.; Nikitakis, N. G.; Sauk, J. J. Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells. Br. J. Cancer. 2004, 91, 1074-1080.
136. Chen, Z.; Colon, I.; Ortiz, N.; Callister, M.; Dong, G.; Pegram, M. Y.; Arosarena, O.; Strome, S.; Nicholson, J. C.; Van Waes, C. Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res. 1998, 58, 3668-3676.
137. Chen, Z.; Malhotra, P. S.; Thomas, G. R.; Ondrey, F. G.; Duffey, D. C.; Smith, C. W.; Enamorado, I.; Yeh, N. T.; Kroog, G. S.; Rudy, S.; McCullagh, L.; Mousa, S.; Quezado, M.; Herscher, L. L.; Van Waes, C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 1999, 5, 1369-1379.
138. Ondrey, F. G.; Dong, G.; Sunwoo, J.; Chen, Z.; Wolf, J. S.; Crowl-Bancroft, C. V.; Mukaida, N.; Van Waes, C. Constitutive activation of transcription factors NF-(kappa)B, AP-I, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol. Carcinog. 1999, 26, 119-129.
139. Turkson, J.; Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19, 6613-6626.
140. Buettner, R.; Mora, L. B.; Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8, 945-954.
141. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
142. Ni, Z.; Lou, W.; Leman, E. S.; Gao, A. C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000, 60, 1225-1228.
143. Mora, L. B.; Buettner, R.; Seigne, J.; Diaz, J.; Ahmad, N.; Garcia, R.; Bowman, T.; Falcone, R.; Fairclough, R.; Cantor, A.; Muro-Cacho, C.; Livingston, S.; Karras, J.; Pow-Sang, J.; Jove, R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62, 6659-6666.
144. Niu, G.; Bowman, T.; Huang, M.; Shivers, S.; Reinigen, D.; Daud, A.; Chang, A.; Kraker, A.; Jove, R.; Yu, H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002, 21, 7001-7010.
145. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25, 67-73.
146. Grandis, J. R.; Sok, J. C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther 2004, 102, 37-46.
147. Ang, K. K.; Andratschke, N. H.; Milas, L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol Biol. Phys. 2004, 58, 959-65.
148. Buerger, C.; Nagel-Wolfrum, K.; Kunz, C.; Wittig, I.; Butz, K.; Hoppe-Seyler, F.; Groner B. Sequence-specific Peptide Aptamers, Interacting with the Intracellular Domain of the Epidermal Growth Factor Receptor, Interfere with Stat3 Activation and Inhibit the Growth of Tumor Cells. J. Biol. Chem. 2003, 278, 37610-37621.
149. Shao, H.; Cheng, H. Y.; Cook, R. G.; Tweardy, D. J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003, 63, 3923-3930.
150. Wang, L. H.; Yang, X. Y.; Mihalic, K.; Xiao, W.; Li, D.; Farrar, W. L. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator P1AS3. J. Biol. Chem. 2001, 276, 31839-31844.
151. Song, H.; Sondak, V. K.; Barber, D. L.; Reid, T. J.; Lin, J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int. J. Oncol. 2004, 24, 1017-1026.
152. He, B.; You, L.; Uematsu, K.; Zang, K.; Xu, Z.; Lee, A. Y.; Costello, J. F.; McCormick, F.; Jablons, D. M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. USA 2003, 100, 14133-14138.
153. Quadros, M. R.; Peruzzi, F.; Kari, C.; Rodeck, U. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res. 2004, 64, 3934-3939.
154. Konnikova, L.; Kotecki, M.; Kruger, M. M.; Cochran, B. H. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003, 3, 23.
155. Li, L.; Shaw, P. E. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J. Biol. Chem. 2002, 277, 17397-17405.
156. Song, L.; Turkson, J.; Karras, J. G.; Jove, R.; Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22, 4150-4165.
157. Nakajima, K.; Yamanaka, Y.; Nakae, K.; Kojima, H.; Ichiba, M.; Kiuchi, N.; Kitaoka, T.; Fukada, T.; Hibi, M.; Hirano, T. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in Ml leukemia cells. EMBO J. 1996, 15, 3651-3658.
158. Niu, G.; Heller, R.; Catlett-Falcone, R.; Coppola, D.; Jaroszeski, M.; Dalton, W.; Jove, R.; Yu, H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999, 59, 5059-5063.
159. Turkson, J.; Ryan, D.; Kim, J. S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A. D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 2001, 276, 45443-45455.
160. Turkson, J.; Kim, J. S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A. D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004, 3, 261-269.
161. Bild, A. H.; Turkson, J.; Jove, R. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 2002, 21, 3255-3263.
162. Leong, P. L.; Andrews, G. A.; Johnson, D. E.; Dyer, K. F.; Xi, S.; Mai, J. C.; Robbins, P. D.; Gadiparthi, S.; Burke, N. A.; Watkins, S. F.; Grandis, J. R. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 2003, 100, 4138-4143.
163. Jing, N.; Li, Y.; Xu, X.; Sha, W.; Li, P.; Feng, L.; Tweardy, D. J. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol. 2003, 22, 685-696.
164. Jing, N.; Li, Y.; Xiong, W.; Sha, W.; Jing, L.; Tweardy, D. J. G-Quartet Oligonucleotides: A New Class of Signal Transducer and Activator of Transcription 3 Inhibitors That Suppresses Growth of Prostate and Breast Tumors through Induction of Apoptosis. Cancer Res. 2004, 64, 6603-6609.
165. Niu, G.; Shain, K. H.; Huang, M.; Ravi, R.; Bedi, A.; Dalton, W. S.; Jove, R.; Yu, H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001, 61, 3276-3280.
166. Nikitakis, N. G.; Hamburger, A. W.; Sauk, J. J. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res. 2002, 62, 1004-1007.
167. Nikitakis, N. G.; Hebert, C.; Lopes, M. A.; Reynolds, M. A.; Sauk, J. J. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int. J. Cancer 2002, 98, 817-823.
168. Hong, S. H.; Ondrey, F. G.; Avis, I. M.; Chen, Z.; Loukinova, E; Cavanaugh, P. F. Jr.; Van Waes, C.; Mulshine, J. L. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J. 2000, 14, 1499-1507.
169. Nikitakis, N. G.; Siavash, H.; Hebert, C.; Reynolds, M. A.; Hamburger, A. W.; Sauk, J. J. 15-PGJ2, but not thiazoudinediones, inhibits cell growth, induces apoptosis, and causes downregulation of Stat3 in human oral SCCa cells. Br. J. Cancer 2002, 57, 1396-1403.
170. Siavash, H.; Nikitakis, N. G.; Sauk, J. J. Targeting of epidermal growth factor receptor by cyclopentenone prostaglandin 15-Deoxy-Delta 12,14-prostaglandin J2 in human oral squamous carcinoma cells. Cancer Lett. 2004, 211, 97-103.
171. Toma, S.; Monteghirfo, S.; Tasso, P.; Nicolo, G.; Spadini, N.; Palumbo, R.; Molina, F. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines. Cancer Lett. 1994, 82, 209-216.
172. Lingen, M. W.; Polverini, P. J.; Bouck, N. P. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998, 55, 5551-5558.
173. Goncalves, A.; Camerlo, J.; Bun, H.; Gravis, G.; Genre, D.; Bertucci, F.; Resbeut, M.; Pech-Gourg, F.; Durand, A.; Maraninchi, D.; Viens, P. Phase 11 study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. 2001, 21, 1431-1437.
174. Le Gouill, S.; Pellat-Deceunynck, C.; Harousseau, J. L.; Rapp, M. J.; Robillard, N.; Bataille, R.; Amiot, M. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002, 16, 1664-1667.
175. Alsina, M.; Fonseca, R.; Wilson, E. F.; Belle, A. N.; Gerbino, E.; Price-Troska, T.; Overton, R. M.; Ahmann, G.; Bruzek, L. M.; Adjei, A. A.; Kaufmann, S. H.; Wright, J. J.; Sullivan, D.; Djulbegovic, B.; Cantor, A. B.; Greipp, P. R.; Dalton, W. S.; Sebti, S. M. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004, 103, 3271-3277.
176. Chun, K. H.; Lee, H. Y.; Hassan, K.; Khuri, F.; Hong, W. K.; Lotan, R. Implication of protein kinase B/Akt and Bcl-2/Bcl-xL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 2003, 63, 4796-4800.
177. Blaskovich, M. A.; Sun, J.; Cantor, A.; Turkson, J.; Jove, R.; Sebti, S. M. Discovery of JS1-124 (cucurbitacin 1), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63, 1270-1279.
178. Takeda, K.; Noguchi, K.; Shi, W.; Tanaka, T.; Matsumoto, M.; Yoshida, N.; Kishimoto, T.; Akira, S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. USA 1997, 94, 3801-3804.
179. Liu, X.; Robinson, G. W.; Wagner, K. U.; Garrett, L.; Wynshaw-Boris, A.; Hennighausen, L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11, 179-186.
180. Douglas, W. G.; Tracy, E.; Tan, D.; Yu, J.; Hicks, W. L. Jr.; Rigual, N. R.; Loree, T. R.; Wang, Y.; Baumann, H. Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol. Cancer Res. 2004, 2, 585-593.